MarketPulse

lanifibranor

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Bolsters Leadership Ranks Ahead of Pivotal Lanifibranor Phase 3 Data

Inventiva appoints three senior executives to strengthen leadership before Phase 3 lanifibranor data readout expected Q4 2026.
BNTXIVAbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Bolsters Executive Team Ahead of Critical Lanifibranor Phase 3 Data

Inventiva appoints three new executives to strengthen leadership before anticipated Phase 3 lanifibranor trial results expected in Q4 2026.
IVAGeneral CounselPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files 2025 Earnings as Cash Position Supports MASH Drug Development

Inventiva filed 2025 regulatory documents with €99.3M cash on hand, advancing lanifibranor Phase 3 trial for metabolic liver disease treatment.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files Annual Reports With €230.9M Cash Pile Amid MASH Drug Development

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Inventiva

Inventiva Reports €99.3M Cash Position Following $172.5M Capital Raise

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.
IVAcash positionfinancing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical